Stomach cancer · Gastroenterology · 2020
Summary: stomach-cancer patients with more of the protein DDIT4 die sooner. Its data: they live longer.
Did patients with more DDIT4 live longer or die sooner than those with less?
The paper says
Researchers tested 509 stomach-cancer patients’ tumors for DDIT4, a protein the paper says slows the growth of cells with damaged DNA. Its summary says “Lower DDIT4 expression correlated with longer survival”: patients whose tumors made less of it lived longer; those with more died sooner.
Its own data show
The paper’s survival chart shows the reverse: the 200 patients with more DDIT4 lived longer than the 309 with less. Chance alone would produce a gap this big only about 1 time in 50 if DDIT4 made no difference (p = 0.021). The paper’s four other passages on this result agree with the chart.
A paper’s summary is the paragraph most people read, often the only part. Read alone, this one makes more DDIT4 look like bad news, the reverse of what the study found. Changing “lower” to “higher” would fix it. PubMed and Europe PMC, the free databases where most readers see it, carry the same backwards sentence; no correction has been issued.